Ground-Breaking Data from the Phase III ADAURA Trial

A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).

Related Videos
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Aaron Gerds, MD, MS, an expert on myelofibrosis
Stephen Oh, MD, PhD, an expert on myelofibrosis
Stephen Oh, MD, PhD, an expert on myelofibrosis
Stephen Oh, MD, PhD, an expert on myelofibrosis